PHARMACEUTICAL IP

  • Offering
    • Evolve AI
      • Albert
        • Validity analysis
        • Albert Construe
      • Popper
      • Franklin
      • AI for Sequences
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert
      • Validity analysis
      • Albert Construe
    • Popper
    • Franklin
    • AI for Sequences
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
    • Evolve AI
      • Albert
        • Validity analysis
        • Albert Construe
      • Popper
      • Franklin
      • AI for Sequences
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert
      • Validity analysis
      • Albert Construe
    • Popper
    • Franklin
    • AI for Sequences
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team

Bad cases make bad law: Has DABUS “the AI inventor” actually invented anything?

  • Technology: AI drug discovery
  • 16th September 2023
In keeping with the so-called media "silly season" of late summer, we thought we would check in on the AI inventor debate. We have been sceptical about Dr Thaler and his purported inventing machine, DABUS, for some time. A recent EPO Examining Division office action appears to share similar concerns. 
Gold band splitting into three branches at a turquoise junction on dark blue, Evolve abstract article image

This post is based on a previous article on IPKat.

In the pending European DABUS case (EP4067251), DABUS’s invention as originally claimed was found to lack novelty in view of 25 year old prior art. After amendment, the EPO now finds the claimed invention insufficiently disclosed and to lack inventive step. It is the insufficiency objection that is particularly revealing. The insufficiency attack demonstrates the random and abstract nature of the purported inventions, and highlights the practical and commercial irrelevance of the DABUS dispute to the burgeoning commercial landscape of creative AI such as ChatGPT. 

Evolve AI

AI inventor case catch-up: Formalities, not patentability

It is worth remembering that a patent application may be filed for any subject matter, provided the appropriate forms are filled in and the necessary fees paid. The process of patent prosecution determines whether the application contains an invention that may be awarded a patent. In most jurisdictions, this will require the invention to be sufficiently disclosed and to be novel, non-obvious and possessing of utility. 

No court or patent office has thus far found the subject matter claimed in the DABUS patent applications patentable. In most cases, the patent offices haven’t even got around to actually assessing the patentability of the claimed invention. The patent applications have simply been refused for failing to satisfy the formal requirements of filing. Notably, South Africa, the only jurisdiction to grant a DABUS patent, does not substantively examine patentability. We are currently waiting for the decision from the UK Supreme Court on the UK DABUS case. However, as with the courts in other jurisdictions, the UK Supreme Court is not assessing the patentability of the AI-derived invention, whether the AI actually invented the invention, or even if anything has actually been invented. The Supreme Court is merely considering whether an AI may be formally designated as an inventor on a UK patent.

Has DABUS invented?

The EPO refused the European DABUS applications (EP3564144 and EP3563896) in 2021 for failing to satisfy the formal requirement of naming a human inventor (J 08/20). Undaunted, Dr Thaler filed a divisional application for one of these cases (EP4067251). Unsurprisingly, the Examining Division has indicated that the divisional application will be refused for failing to designate an inventor. 

The EPO Examining Division has now also made some remarks on the patentability of the claimed subject-matter. Claim 1 of the patent application specifies a cylindrical food or beverage container, formed from a wall with a “fractal profile”. The Examining Division indicates that the claims lack inventive step. In particular, the Examiner argues that the distinguishing feature of the claims in view of the cited prior art:

“do not appear to provide any special technical effect over [the closest prior art], and therefore to solve any problem. They can therefore only be considered as a design option that the skilled person would choose for non-technical reasons, and for this reason the subject-matter of claim 1 does not involve an inventive step“. 

Unusually for a mechanical invention, the Examiner also argues that the application lacks sufficiency (Article 83 EPC). The Examiner observes:

 “The description is silent about how to obtain a fractal profile for the wall of the container. Instead, it explains that ‘the skilled person will appreciate that the profile of the wall will not be pure fractal form but will have a form dictated by practical considerations such as the minimum practical or desirable size of its fractal components’. How this minimum practical or desirable size has to be determined is not explained. Neither is explained what a fractal profile (claim 1) which would not be of pure form (description) can be, let alone how it can be obtained“. 

In other words, according to the current assessment of the EPO, not only does the subject matter produced by DABUS lack inventive step, but a skilled person would also not know how to even make the invention. The EPO is thus not just refusing to permit designation of DABUS as an inventor, it is highly sceptical that the subject-matter ascribed to DABUS is actually a patentable invention. 

Final thoughts

It is an adage of the legal profession that bad cases make bad law. According to a recent profile piece in the Economist, Dr Thaler has apparently fallen in love with DABUS. Perhaps herein lies the problem. 

A notable characteristic of the DABUS dispute is the apparent lack of a commercial product covered by the patent applications. After all, patent prosecution and maintenance, not to mention legal proceedings before the UK and US courts, is an expensive business. There is however no indication that Dr Thaler is interested in commercialising a fractal-patterned food container. As such, the whole dispute appears to be an academic exercise. We doubt that anyone with a commercially valuable product to protect would have any difficulty filling in EPO Form 1002 according to the EPO’s requirements. 

If we ignore the red herring of the DABUS case however, it is clear that the commercially relevant question raised by the possibility of AI inventorship is not inventorship, but ownership. It is the owner of an invention, and not the inventor who reaps the rewards of patent protection. Notably, Dr Thaler seems to have no difficulty in claiming ownership of DABUS’s purported inventions. However, in true cases of AI inventorship, we predict that ownership issues will be front and centre, particularly ownership issues surrounding the algorithms and their training data. These legal disputes will not be qualitatively different from those relating to any platform technology. 

In the meantime, the patent and AI communities will continue to raise an ironical eyebrow at the mainstream media reports of DABUS the inventing AI. 

Related insights...

Twisting strand of gold beads with a turquoise section on dark blue, Evolve biotechnology image
Twisting strand of gold beads with a turquoise section on dark blue, Evolve biotechnology image

AI for patent sequences: Avoiding costly sequence errors

  • 6th November 2026
A single wrong residue can mean a patent does not cover the product. Evolve’s AI Sequence Agents build ST.26 listings in code, check every residue, keep the claims covering the lead in line with the IP strategy from drafting to grant, and check the sequences in granted patents.
Grid of gold cubes with one turquoise cube lifted on dark blue, Evolve AI drug discovery image
Grid of gold cubes with one turquoise cube lifted on dark blue, Evolve AI drug discovery image

AI in the patent industry: Instant coffee Copilot

  • 4th November 2026
It is now abundantly clear that AI cannot be ignored by the patent industry. However, amongst the private practice firms, there still remains a divergence of approach, with many attorneys still not using AI in their day-to-day practice.
Ordered block of gold plates with three turquoise plates lifted out on dark blue, Evolve abstract article image
Ordered block of gold plates with three turquoise plates lifted out on dark blue, Evolve abstract article image

AI in the patent industry: The sneaky practice of prompt injection (and what to do about it)

  • 30th October 2026
As patent attorneys, we are by now all hopefully well versed in the confidentiality and hallucination risks of using AI. However, as AI tools are increasingly used to read, summarise and come to conclusions about third-party documents, there is another risk we need to think about: prompt injection. This is the sneaky practice of hiding…
Pyramid of gold spheres with a turquoise apex and pink equator line on dark blue, Evolve Franklin image
Pyramid of gold spheres with a turquoise apex and pink equator line on dark blue, Evolve Franklin image

Franklin: AI-powered publication review for pharma

  • 23rd October 2026
Publication screening is a time sink for pharma patent attorneys. Franklin quickly finds the undisclosed inventions in a new publication submission.
Turquoise sphere held in gold gyroscope rings with a pink edge line on dark blue, Evolve Albert image
Turquoise sphere held in gold gyroscope rings with a pink edge line on dark blue, Evolve Albert image

Albert – Construe: defining your claims before they are defined for you.

  • 25th September 2026
Albert – Construe is the latest addition to Evolve’s proprietary AI toolkit.  It construes a set of claims, sets out with supporting evidence what each unclear term means, highlights any inconsistencies caused by other disclosures within an application, and flags where amendments may have changed the scope of a claim term.
Ordered block of gold plates with three turquoise plates lifted out on dark blue, Evolve abstract article image
Ordered block of gold plates with three turquoise plates lifted out on dark blue, Evolve abstract article image

AI in the patent industry: Beware the MCP Trojan horse

  • 11th September 2026
As patent attorneys, we should all know by now not to put client confidential information into a non-enterprise version of an LLM. However, as the capabilities of AI tools become more complex, so too does the necessity of understanding what exactly they are doing and where our data goes, beyond the simple prompt.
Gold bar dissolving into turquoise fragments at its centre on dark blue, Evolve abstract article image
Gold bar dissolving into turquoise fragments at its centre on dark blue, Evolve abstract article image

AI in the patent industry: Bubble trouble and the affordability myth

  • 20th July 2026
Whenever we write about AI, responses have started to move away from talk about hallucination, confidentiality or quality. The new concern is one of economics, i.e. will the whole AI thing just become too expensive and are we putting ourselves at risk by outsourcing to AI.
Ordered block of gold plates with three turquoise plates lifted out on dark blue, Evolve abstract article image
Ordered block of gold plates with three turquoise plates lifted out on dark blue, Evolve abstract article image

Podcast: Staring into the AI abyss

  • 14th July 2026
INSIGHT epi – The podcast for European patent professionals
Gold band splitting into three branches at a turquoise junction on dark blue, Evolve abstract article image
Gold band splitting into three branches at a turquoise junction on dark blue, Evolve abstract article image

AI in the patent industry: The risks of AI shadow use

  • 8th July 2026
In many patent firms, permission to use AI tools is currently restricted to the most senior individuals. Whilst almost every firm seems to have a dedicated “AI task-force” these days to trial new software, this group is usually restricted to partners or senior associates, whilst trainees and more junior associates are denied access to AI…
Turquoise sphere held in gold gyroscope rings with a pink edge line on dark blue, Evolve Albert image
Turquoise sphere held in gold gyroscope rings with a pink edge line on dark blue, Evolve Albert image

Albert: AI-powered competitive intelligence and IP validity analysis for biotech & pharma

  • 23rd June 2026
Expert analysis based on deep industry expertise, delivered quickly and cost-effectively.
All Insights

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2026 All Rights Reserved

Keep in touch

  • Subscribe
  • Contact us
  • Cookie Notice
  • Complaints Procedure
  • Privacy notice
  • Subscribe
  • Contact us
  • Cookie Notice
  • Complaints Procedure
  • Privacy notice